Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objectives: Nab-paclitaxel has radiosensitizing antitumor efficacy in pancreatic cancer. We aimed to establish maximum tolerated dose (MTD) of nab-paclitaxel with radiotherapy in unresectable locally advanced pancreatic cancer.
Methods: In a phase I dose escalation trial patients received weekly nab-paclitaxel for 6 weeks with external beam radiotherapy (EBRT). 3 + 3 design was used with nab-paclitaxel doses: 25 mg/m 2 (cohort 1), 50 mg/m 2 (cohort 2), 75 mg/m 2 (cohort 3), and 100 mg/m 2 (cohort 4). Primary endpoint was MTD. Secondary objectives were progression-free survival and overall survival.
Results: Fourteen patients were recruited. Median age was 69 years (range, 40-86). Grade 1/2 toxicities were nausea (93%), vomiting (54%), diarrhea (57%), and fatigue (69%). There were no dose limiting toxicities (DLT) in cohorts 1 to 3. In cohort 4, DLTs of febrile neutropenia and enterocolitis were observed in patient 1. Subsequent DLT of febrile neutropenia and enterocolitis occurred in patient 5 in the expanded cohort. Following chemoradiotherapy median progression-free survival was 4.7 months (95% confidence interval, 2.5-27.5) and median overall survival was 10.8 months (95% confidence interval, 6.37-25.2).
Conclusions: Nab-paclitaxel and EBRT was well-tolerated at doses below 100 mg/m 2 . The MTD and recommended phase II study dose for nab-paclitaxel with EBRT is 75 mg/m 2 in this disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/MPA.0000000000002065 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Long-term outcome of mycophenolate mofetil after a single dose of rituximab in childhood-onset refractory idiopathic nephrotic syndrome.
Clin Exp Nephrol
September 2025
Department of Pediatrics, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa, 236-0004, Japan.
Background: Maintenance therapy using immunosuppressive agents after rituximab can be effective for sustaining remission in childhood-onset refractory frequently relapsing nephrotic syndrome/steroid-dependent nephrotic syndrome (FRNS/SDNS). We evaluated the long-term outcome of mycophenolate mofetil (MMF) after rituximab.
Methods: We conducted a multicenter, retrospective cohort study of patients with childhood-onset refractory FRNS/SDNS who received MMF as maintenance therapy after a single dose of rituximab and were followed up ≥ 2 years at three pediatric renal centers.
Weekly Cisplatin and 5-Fluorouracil in Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Pandemic-Era Evaluation.
Medicina (Kaunas)
July 2025
Department of Radiation Oncology, Taichung Veterans General Hospital, Taichung 407219, Taiwan.
: The COVID-19 pandemic disrupted cancer care, prompting adaptations to reduce patient exposure while preserving treatment efficacy. This retrospective observational study compared a weekly cisplatin and 5-fluorouracil (5-FU) regimen to the standard monthly regimen for neoadjuvant chemoradiotherapy in patients with locally advanced esophageal squamous cell carcinoma. : This single-center retrospective study included 91 patients, divided into two cohorts: weekly chemotherapy (n = 30) and standard chemotherapy (n = 61).
View Article and Find Full Text PDFEndometrial thickness as a predictor of methotrexate treatment success in ectopic pregnancy: A prospective cohort study.
J Obstet Gynaecol Res
August 2025
Obstetrics & Gynecology Department, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Aim: Ectopic pregnancy (EP) remains a significant cause of first-trimester maternal morbidity and mortality. Methotrexate (MTX) is an effective non-surgical treatment for selected early pregnancy cases; however, predicting treatment success remains challenging. Endometrial thickness (ET) has been suggested as a potential predictor, though its clinical utility remains uncertain.
View Article and Find Full Text PDFEfficacy and safety of neoadjuvant toripalimab plus chemotherapy in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma (NICE): a multicentre, single-arm, exploratory phase 2 study.
EClinicalMedicine
September 2025
Department of General Surgery, Nanfang Hospital, Southern Medical University, 1838 North Guangzhou Avenue, Guangzhou, Guangdong, China.
Background: In locally advanced gastric or gastroesophageal junction adenocarcinoma (GC/EGJC), deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) tumors exhibit high responsiveness to immunotherapy. The synergistic efficacy of neoadjuvant immunotherapy combined with chemotherapy in dMMR/MSI-H GC/EGJC remains uncertain.
Methods: The NICE trial is a multicentre, single-arm, exploratory phase 2 study conducted at six hospitals in China, evaluating the safety and efficacy of toripalimab in combination with CapeOX as perioperative therapy for locally advanced GC/EGJC across three biomarker-defined cohorts.
Neoadjuvant chemoradiation with camrelizumab and nimotuzumab for initially inoperable esophageal squamous cell carcinoma: A single-arm phase 2 trial.
Eur J Cancer
August 2025
Department of Radiation Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine. Universityof Science and Technology of China, Hefei, Anhui 230001, China; Core Facility Center, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University
Background: Neoadjuvant regimen with a high surgical conversion rate was warranted for initially inoperable patients with locally advanced esophageal squamous cell carcinoma (LAESCC). To evaluate the efficacy and safety of neoadjuvant chemoradiotherapy combined with camrelizumab and nimotuzumab (NCRCN) followed by surgery in initially inoperable patients with LAESCC.
Methods: This cohort study was a prospective, one-arm, phase 2 study from December 2021 to December 2023.